Status:

UNKNOWN

Pharmacogenetic and Neurofunctional Brain Areas Study in Obese Patients With Binge Eating Disorder

Lead Sponsor:

Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente

Conditions:

Obesity

Binge Eating Disorder

Eligibility:

All Genders

18-50 years

Brief Summary

Adoption, twin and family studies have reported that obesity has a strong heritable component and in particular, it has been suggested that BMI in adults is due to genetic influence rather than shared...

Detailed Description

Obesity has been declared the number one illness of the 21st Century in industrialized countries, and is reaching epidemic proportions. Adoption, twin and family studies have reported that obesity has...

Eligibility Criteria

Inclusion

  • Patients of Eating Disorders Clinic with a diagnosis of Bulimia Nervosa, Eating Disorders Not Otherwise Specified 3 and 6 with Binge Eating Disorder according to research criteria in Diagnostic and Statistical of Mental Disorders, version IV revised, who started taking Topiramate.
  • Probands with diagnosis of obesity (BMI ≥30 kg/m2- 40 kg/m2).
  • Capable to give written informed consent.
  • Age of 18 to 50 years at screening.
  • Maternal and paternal grandparents of Mexican descent.
  • Probands without psychopharmacological treatment (including anticonvulsants) at least 4 weeks before inclusion.

Exclusion

  • Subjects with alcohol or substance abuse or dependence.
  • Any psychiatric or medical disorder that requires inpatient treatment.
  • Psychosis or suicidal thoughts.
  • Abnormal blood chemistry.
  • Diabetes uncontrolled.
  • Unstable hypertension or difficult to control (criterion 7 of inclusion section).
  • Metabolic acidosis.
  • Narrow-angle glaucoma.
  • Unstable hypothyroidism or hyperthyroidism.
  • Unable or unwilling to give a blood sample.
  • Pace-makers or metal implants that would preclude the functional Magnetic Resonance Image scan.
  • Pregnant or lactating women at screening or positive blood pregnancy test.
  • Presence of any epileptic disorder.
  • Subjects unable or unlikely to follow the protocol procedures.

Key Trial Info

Start Date :

June 1 2013

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

March 1 2014

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT01868204

Start Date

June 1 2013

End Date

March 1 2014

Last Update

June 4 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Instituto Nacional de Psiquiatria Ramon de la Fuente Muñiz

México, D.f., Mexico, 14370